vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Sunlands Technology Group (STG). Click either name above to swap in a different company.

Sunlands Technology Group is the larger business by last-quarter revenue ($10.1M vs $8.1M, roughly 1.2× Arcellx, Inc.). Sunlands Technology Group runs the higher net margin — 24.0% vs -766.0%, a 790.0% gap on every dollar of revenue. Over the past eight quarters, Sunlands Technology Group's revenue compounded faster (0.6% CAGR vs -24.6%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.

ACLX vs STG — Head-to-Head

Bigger by revenue
STG
STG
1.2× larger
STG
$10.1M
$8.1M
ACLX
Higher net margin
STG
STG
790.0% more per $
STG
24.0%
-766.0%
ACLX
Faster 2-yr revenue CAGR
STG
STG
Annualised
STG
0.6%
-24.6%
ACLX

Income Statement — Q1 FY2025 vs Q3 FY2025

Metric
ACLX
ACLX
STG
STG
Revenue
$8.1M
$10.1M
Net Profit
$-62.3M
$2.4M
Gross Margin
88.5%
Operating Margin
-847.6%
26.5%
Net Margin
-766.0%
24.0%
Revenue YoY
-79.3%
Net Profit YoY
-765.1%
EPS (diluted)
$-1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
STG
STG
Q3 25
$10.1M
Q2 25
$9.3M
Q1 25
$8.1M
Q4 24
$15.3M
$9.7M
Q3 24
$26.0M
Q2 24
$27.4M
$10.0M
Q1 24
$39.3M
Q4 23
$63.1M
Net Profit
ACLX
ACLX
STG
STG
Q3 25
$2.4M
Q2 25
$1.4M
Q1 25
$-62.3M
Q4 24
$-47.1M
$1.8M
Q3 24
$-25.9M
Q2 24
$-27.2M
$2.2M
Q1 24
$-7.2M
Q4 23
$19.8M
Gross Margin
ACLX
ACLX
STG
STG
Q3 25
88.5%
Q2 25
85.2%
Q1 25
Q4 24
83.3%
Q3 24
Q2 24
85.2%
Q1 24
Q4 23
Operating Margin
ACLX
ACLX
STG
STG
Q3 25
26.5%
Q2 25
15.2%
Q1 25
-847.6%
Q4 24
-348.2%
13.4%
Q3 24
-129.1%
Q2 24
-127.8%
Q1 24
-40.3%
Q4 23
23.8%
Net Margin
ACLX
ACLX
STG
STG
Q3 25
24.0%
Q2 25
15.4%
Q1 25
-766.0%
Q4 24
-308.4%
18.2%
Q3 24
-99.4%
Q2 24
-99.3%
21.5%
Q1 24
-18.3%
Q4 23
31.4%
EPS (diluted)
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
$-1.13
Q4 24
$-0.87
Q3 24
$-0.48
Q2 24
$-0.51
$0.31
Q1 24
$-0.14
Q4 23
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
STG
STG
Cash + ST InvestmentsLiquidity on hand
$543.3M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
$17.7M
Total Assets
$648.1M
$41.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
STG
STG
Q3 25
$15.1M
Q2 25
Q1 25
$543.3M
Q4 24
$587.4M
$15.6M
Q3 24
$574.3M
Q2 24
$516.7M
$18.7M
Q1 24
$573.9M
Q4 23
$702.0M
Total Debt
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
Q4 24
$1.5M
Q3 24
Q2 24
$1.8M
Q1 24
Q4 23
Stockholders' Equity
ACLX
ACLX
STG
STG
Q3 25
$17.7M
Q2 25
$12.6M
Q1 25
$416.9M
Q4 24
$454.8M
$10.7M
Q3 24
$483.0M
Q2 24
$487.2M
$7.6M
Q1 24
$496.6M
Q4 23
$485.4M
Total Assets
ACLX
ACLX
STG
STG
Q3 25
$41.2M
Q2 25
$40.3M
Q1 25
$648.1M
Q4 24
$711.3M
$42.4M
Q3 24
$764.9M
Q2 24
$734.3M
$41.3M
Q1 24
$779.7M
Q4 23
$825.1M
Debt / Equity
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
Q4 24
0.14×
Q3 24
Q2 24
0.24×
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
STG
STG
Operating Cash FlowLast quarter
$-63.1M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
$-63.1M
Q4 24
$-46.0M
Q3 24
$30.7M
Q2 24
$-36.2M
Q1 24
$-31.9M
Q4 23
$58.2M
Free Cash Flow
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
Q2 24
$-39.5M
Q1 24
$-38.3M
Q4 23
$53.0M
FCF Margin
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
Q2 24
-144.1%
Q1 24
-97.7%
Q4 23
83.9%
Capex Intensity
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
Q2 24
11.7%
Q1 24
16.4%
Q4 23
8.4%
Cash Conversion
ACLX
ACLX
STG
STG
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
2.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons